A gut-skin formulation for distribution partners
A gut-skin category for the psoriasis marketin Europe.
en-CLEAR is a gut-skin axis formulation designed by the Enbiosis Digital Twin & AI Engine, the same engine behind en-TEAR. We are appointing one exclusive partner per territory.
- Gold, UK Tech Rocketship Awards 2022
- AI-designed formulation
- 90-day programme
AI-generated visualisation. Not a result of en-CLEAR.
The people
Psoriasis is part of daily life for millions of people.
100M
people
Approximately 100 million people worldwide live with psoriasis, by self-reported estimates.
Global Psoriasis Atlas, 2025: 102 million self-reported, 43 million physician-diagnosed. WHO Global Report on Psoriasis, 2016.
The engine
Most supplements start with an ingredient. en-CLEAR starts with a target.
The usual way to build a supplement is to take a known ingredient and look for an effect. The Enbiosis engine works in reverse: it models what the gut microbiome needs to produce, then designs the food-grade inputs that get it there.
The usual way
The Enbiosis engine
Inside the model
Every formulation starts as a simulation.
Inside the model
Simulate
Select
Formulate
The product
One programme. One daily routine. Ninety days.
A daily food supplement, designed around the gut-skin axis from the first line of the formula. Built to sit inside an existing routine, not to replace a varied and balanced diet.
- Category
- Food supplement
- Programme
- 90 days, three 600 g jars
- Axis
- Gut-skin
- Designed by
- Enbiosis Digital Twin & AI Engine
Available as
- Finished product
- Premix
- Licensed formulation
The comparison
The difference is where the design starts.
Comparing approaches is more useful than comparing brands: each row shows how a common approach is built and the question it leaves open.
Skin-level care
Creams, serums, cleansers
- Starts from
- The skin surface
- How it works
- Acts directly on the skin, from the outside in.
- The open question
- The gut sits outside its scope.
Beauty supplements
Collagen, biotin, hyaluronic acid, zinc, vitamin C
- Starts from
- A familiar ingredient
- How it works
- Formulas are built around well-known ingredients.
- The open question
- Familiarity is not the same as a defined gut target.
Live probiotics
Single strains or multi-strain blends
- Starts from
- A bacterial strain
- How it works
- Selected bacteria are added to the gut.
- The open question
- Effects depend on the strain, and survival and colonisation vary from person to person.
Single-pathway actives
One compound or one botanical
- Starts from
- One mechanism
- How it works
- One ingredient is chosen for one biological pathway.
- The open question
- Many factors shape skin, so one pathway rarely explains all of it.
Long-list blends
Many actives in one product
- Starts from
- A list of actives
- How it works
- Many recognisable ingredients are combined in one product.
- The open question
- Overlapping roles make it hard to say what each ingredient does.
en-CLEAR
Designed by the Enbiosis Digital Twin & AI Engine
- Starts from
- Target metabolites
- How it works
- A digital twin of the gut models microbial metabolism. AI then selects the food-grade precursors predicted to lead to the target metabolites.
- The open question
- Its own clinical study is in preparation.
Approaches, not brands: each row describes a common approach, not every product built on it. en-CLEAR is a food supplement, not a substitute for skin care or medical care.
The category has room for a product designed from the gut.
Why the gut
Psoriasis shows on the skin. Research is also looking at the gut.
Studies comparing people with and without psoriasis report differences in the gut. They show associations, not proof of cause, and they are why research now looks at the gut-skin axis.
01
A different gut microbiome
Compared with healthy controls, studies report a different gut microbiome in people with psoriasis, often involving bacteria that produce short-chain fatty acids. Specific signatures vary between studies.1
02
Gut barrier markers
Small cross-sectional studies found higher blood markers of gut barrier disruption, such as I-FABP and claudin-3, in people with psoriasis, linked to disease severity.2
03
A shared immune pathway
Psoriasis and inflammatory bowel disease share the IL-23/IL-17 immune pathway, and people with psoriasis are more likely to also have Crohn's disease or ulcerative colitis.3
The studies above describe the condition. None of them tested en-CLEAR.
Design rationale
Why en-CLEAR starts in the gut
en-CLEAR is designed from the gut side of the gut-skin axis. The engine sets target metabolites and selects food-grade ingredients predicted to support them. Whether this affects skin has not been tested yet; a clinical study is planned.
Sources
- Gao Y, et al. Pathogens, 2025. doi:10.3390/pathogens14040358. Thye AY, et al. Biomedicines, 2022. doi:10.3390/biomedicines10051037.
- Sikora M, et al. J Clin Med, 2019. doi:10.3390/jcm8071021. Sikora M, et al. J Eur Acad Dermatol Venereol, 2019. doi:10.1111/jdv.15700.
- Fu Y, et al. JAMA Dermatol, 2018. doi:10.1001/jamadermatol.2018.3631.
The proof
The engine behind en-CLEAR already has clinical results.
en-TEAR · the engine's first formulation
+67%
Tear production at 16 weeks (Schirmer test, 10.0 → 16.7 mm), eight weeks after intake had stopped. Now in a placebo-controlled randomised trial with a planned 130 participants (NCT07453212).
Pilot: single-arm, open-label, n=20 (NCT07148271). Article submitted for peer review.
The Enbiosis algorithm · 12 months
Responders at 12 months in the open-label follow-up of a multicentre randomised trial in irritable bowel syndrome (Gut Microbes, 2026).
25 of 40 on the personalised diet, 10 of 29 on low-FODMAP.
en-CLEAR's own study
In preparation
A clinical study of en-CLEAR is in preparation. Once it is registered, the registry number and the centres appear here.
We publish as we go.
Our early user programme starts with the Türkiye launch. Partners receive its reports as the data comes in.
- 5
- placebo-controlled trials running
- 9
- registered clinical studies
- 6
- peer-reviewed papers
The offer
One market. One partner.
You
Register and sell en-CLEAR across your territory.
We
Finished product and full territory exclusivity.
What comes with it
- 01
Your territory, exclusively
No second partner in your market.
- 02
Margin that works
Distributor pricing set for your channel, with volume tiers agreed before launch.
- 03
Launch support
Registration dossier, label draft and launch plan for your market.
- 04
A complete marketing kit
Imagery, education materials and a sales deck.
- 05
Our science team
Direct access for your key accounts and medical advisors.
- 06
The whole portfolio
en-TEAR, en-JOY&FIT and en-MASCULINE through the same relationship.
The route
From first call to first shipment.
Step 1
30-minute call
We talk through your market, your channels and our terms.
Step 2
Territory reserved
We hold your market while we agree terms, and share the distributor pack under NDA.
Step 3
Registration
We prepare the dossier. You file it in your market.
Step 4
First shipment
Product ships with the marketing kit for launch.
Territories
Allocated in the order partners qualify.
- EuropeOpen
- United KingdomOpen
- The GulfOpen
- Central AsiaOpen
- North AfricaOpen
- TürkiyeAllocated · direct to consumer
Your market is not on the list? Ask. We open new territories every quarter.
The company
A microbiome and AI team, with its clinical studies registered on ClinicalTrials.gov.
Founded by Ömer Özkan (CEO), Prof. Özkan Ufuk Nalbantoğlu (CTO) and Aycan Gündoğdu (Chief Science Officer). In operation since 2019, built on microbiome and AI research that predates the company.
- registered clinical studies
- 9
- peer-reviewed papers
- 6
- UK Tech Rocketship Awards 2022
- Gold
- countries using the platform
- 16+
One relationship, four formulations
en-CLEAR
Gut-skin
Now appointing partners
en-TEAR
Gut-eye
On sale in Türkiye
en-JOY&FIT
Gut-metabolic
Open for licensing
en-MASCULINE
Gut-hormone
Open for licensing
Claim a territory
Your market could be next.
Tell us where you sell. We reply within two business days and tell you if your territory is open.
Prefer email? info@enbiosis.com